NYSE · Biotechnology

Biohaven Ltd. (BHVN) Stock

$13.88 -5.51% NYSE: BHVN Healthcare

Valuation

MetricValue
Price$13.88
Market Cap$2.10B
P/E Ratio-2.77
P/B Ratio158.62
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$18.57
52-Week Low$7.48
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-333.00%
ROA-158.29%
ROCE-184.19%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity24.30
Current Ratio3.17

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-219.0M$-568.0M$-436.0M$-885.0M$-745.0M
Net Profit$-214.0M$-570.0M$-408.0M$-846.0M$-739.0M
EPS$-5.97$-12.75$-5.73$-9.28$-6.86
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$142.0M$662.0M$513.0M$615.0M$451.0M
Total Liabilities$47.0M$123.0M$85.0M$192.0M$399.0M
Cash$76.0M$205.0M$248.0M$99.0M$230.0M
Borrowings$3.0M$34.0M$31.0M$37.0M$285.0M

Latest News

Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer GlobeNewswire · Jul 13, 2026 ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership BioPharma Dive · Jul 10, 2026 Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy? Simply Wall St. · Jul 10, 2026 Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer MT Newswires · Jul 9, 2026 Biohaven Announces Scientific Leadership Transitions PR Newswire · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-146.0M$-298.0M$-332.0M$-582.0M$-609.0M
Investing Cash Flow$0$-346.0M$127.0M$-249.0M$300.0M
Financing Cash Flow$138.0M$35.0M$-31.0M$2.0M$0
Net Cash Flow$-6.0M$166.0M$10.0M$-150.0M$130.0M
Free Cash Flow$-147.0M$-339.0M$-335.0M$-587.0M$-610.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.05
EV / EBITDA-3.47
FCF Yield-26.42%
Quick Ratio4.73
Interest Coverage—
Return 1Y6.55%
Return 3Y-38.56%
Return 5Y—

Ownership

Insiders Held11.08%
Institutions Held91.58%
Institutions Float Held102.99%
Institutional HolderSharesReport Date
Janus Henderson Group PLC17,534,6122026-03-31
Blackrock Inc.11,222,4072026-03-31
Suvretta Capital Management, LLC10,286,9372026-03-31
Stifel Financial Corporation9,940,8852026-03-31
State Street Corporation6,618,8032026-03-31

About Biohaven Ltd.

Biohaven Ltd. is led by CEO Vladimir Coric, publicly traded since 2022.

Biohaven Ltd. (BHVN) stock trades at $13.88 with a market capitalization of $2.10B. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.77, reflecting a net loss over the last twelve months, price-to-book of 158.62, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.48 and $18.57, and currently trades 25.3% below its 52-week high.

On profitability, Biohaven Ltd. generates a return on equity (ROE) of -333.00% (negative, reflecting a net loss), return on capital employed of -184.19%.

Biohaven Ltd. by the numbers, 2017–2025

Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-739.0M in 2025.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-587.0M.

Borrowings stand at $285.0M, cash from operations was $-609.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged -486.7% over five years, and was -1421.2% in the most recent year.

The share price itself has compounded at —% a year over five years, -20.4% over three, -22.8% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Biohaven Ltd. (BHVN) — frequently asked questions

What is Biohaven Ltd. (BHVN) stock price today?

Biohaven Ltd. (BHVN) is currently trading at $13.88, down 5.51% today.

What is BHVN P/E ratio?

Biohaven Ltd.'s P/E ratio is -2.77. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is BHVN return on equity (ROE)?

Biohaven Ltd.'s return on equity (ROE) is -333.00%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Biohaven Ltd.'s market cap?

Biohaven Ltd. has a market capitalization of $2.10B.

Does BHVN pay a dividend?

Biohaven Ltd. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does BHVN carry?

Biohaven Ltd. has a debt-to-equity ratio of 24.30. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is BHVN's profit margin?

Biohaven Ltd. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is BHVN in?

Biohaven Ltd. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is BHVN listed on?

Biohaven Ltd. trades on NYSE under the ticker BHVN.

What is BHVN's 52-week range?

Over the last year Biohaven Ltd. has traded between $7.48 and $18.57.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens BHVN currently matches

On the figures above, Biohaven Ltd. passes the filters for 7 of our ready-made screens, among them Day Losers Stocks, High Debt to Equity Stocks, Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Day Losers StocksHigh Debt to Equity StocksStocks Under $100Stocks Under $50Mid Cap StocksNYSE Listed StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.